Nicox
en
fr
Toggle Menu
About Us
Visible Science
Leadership Team
Board of Directors
Glaucoma Advisory Board
Partnerships
Portfolio and Disease Areas
Nicox’s innovative portfolio
Disease focus areas
Our portfolio at a glance
Nitric Oxide Donation
Publications
Investors
Stock Information
Financial and Regulatory Information
Shareholder Meetings
Corporate Presentation
Webcasts
Corporate Governance
News and Events
Press Releases
Events and Conferences
Videos
Contact Us
Contact Details
Main subsidiaries
Job opportunities
Email alerts
Nicox’s HCT 3012 shows equivalent efficacy to rofecoxib without any increase of Systolic Blood Pressure in osteoarthritis patient
June 9, 2004
← Back to blog page
Cookies
By continuing to use this website, you agree to our
Cookie Policy
.
Accept
